Cargando…

Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration

OBJECTIVE: To compare the efficacy of ranibizumab plus fufang xueshuantong capsule (cFXST) with the efficacy of ranibizumab alone in treatment of exudative age-related macular degeneration. METHODS: This prospective, randomized, controlled, pilot study included 38 eyes from 38 patients with exudativ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Hai-Tao, Wang, Jun-Jun, Huang, Jun-Long, Shuai, Yuan-Lu, Li, Jia, Hu, Zi-Zhong, Ding, Yu-Zhi, Liu, Qing-Huai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Prospective Clinical Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520929/ https://www.ncbi.nlm.nih.gov/pubmed/32962487 http://dx.doi.org/10.1177/0300060520931618

Ejemplares similares

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Protective Effects of Fufang Xueshuantong on Diabetic Retinopathy in Rats
por: Duan, Huihui, et al.
Publicado: (2013)

The effect of ranibizumab versus photodynamic therapy on DNA damage in patients with exudative macular degeneration
por: Mozaffarieh, M, et al.
Publicado: (2009)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan, Handan, et al.
Publicado: (2014)

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
por: Barthelmes, Daniel, et al.
Publicado: (2016)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike, Naoko, et al.
Publicado: (2019)

Chinese medicinal formula Fufang Xueshuantong capsule could inhibit the activity of angiotensin converting enzyme
por: Sheng, Shujing, et al.
Publicado: (2014)

Role of ranibizumab in management of macular degeneration
por: Singh, Rishi P, et al.
Publicado: (2007)

Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study
por: Schauwvlieghe, A. M. E., et al.
Publicado: (2016)

The Effect of Ranibizumab on Normal Neurosensory Retina in the Eyes of Patients with Exudative Age Related Macular Degeneration
por: Makri, Olga E., et al.
Publicado: (2017)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
por: Suzuki, Hiroyuki, et al.
Publicado: (2017)

Efficacy and safety of Fufang Xueshuantong Capsules in combination with conventional drugs in the treatment of glaucoma: A meta-analysis and trial sequential analysis
por: Zeng, Zhicheng, et al.
Publicado: (2023)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
por: Nishimura, Yoshihiro, et al.
Publicado: (2012)

One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration
por: Nakamura, Tomoko, et al.
Publicado: (2012)

Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes
por: Figurska, Małgorzata, et al.
Publicado: (2011)

Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration
por: Panos, Georgios D, et al.
Publicado: (2013)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
por: Narayan, Daniel Sanju, et al.
Publicado: (2015)

Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab
por: Perdicchi, Andrea, et al.
Publicado: (2015)

Treatment of age-related macular degeneration: focus on ranibizumab
por: Spitzer, Martin S, et al.
Publicado: (2008)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema
por: Goel, Siddhi, et al.
Publicado: (2019)

Fufang Xueshuantong Improves Diabetic Cardiomyopathy by Regulating the Wnt/β-Catenin Pathway
por: Peng, Meizhong, et al.
Publicado: (2022)

Foveal Exudative Macroaneurysm Treated with Intravitreal Ranibizumab
por: Menezes, Carlos, et al.
Publicado: (2015)

Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients
por: Yamamoto, Akiko, et al.
Publicado: (2013)

Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration
por: Hariprasad, Seenu M., et al.
Publicado: (2012)

Investigation into the potential mechanism and molecular targets of Fufang Xueshuantong capsule for the treatment of ischemic stroke based on network pharmacology and molecular docking
por: Wang, Lei, et al.
Publicado: (2022)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2015)

FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity
por: Monés, Jordi, et al.
Publicado: (2012)

Diabetic papillopathy with macular edema treated with intravitreal ranibizumab
por: Kim, Moosang, et al.
Publicado: (2013)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
por: Karagiannis, Dimitrios A, et al.
Publicado: (2009)

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration
por: Yamada, Kisaburo, et al.
Publicado: (2011)

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017)

Ranibizumab port delivery system in neovascular age-related macular degeneration
por: Chandrasekaran, Priya R., et al.
Publicado: (2022)

Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration
por: Dikmetas, Ozlem, et al.
Publicado: (2022)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong, Angie HC, et al.
Publicado: (2013)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis, Nikolaos, et al.
Publicado: (2016)

Lucentis(®) using Visudyne(®) study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
por: Chen, Eric, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_4a4rqvrtmmr9sjeml5dhv6p85m